Table 1. Presenting clinical and laboratory features of 262 patients with polycythemia vera stratified by the presence of grade 1 or greater bone marrow reticulin fibrosis.
| Variables | All patients (n=262) | Patient without BM reticulin fibrosis (n=135, 52%) | Patients with⩾grade 1 BM reticulin fibrosis (n=127, 48%) | P-value |
|---|---|---|---|---|
| Age at referal in years; median (range) | 62 (17–94) | 64 (20–88) | 60 (17–94) | 0.08 |
| Age⩾60, n (%) | 141 (54%) | 79 (59%) | 62 (49%) | 0.1 |
| Male (%) | 131 (50%) | 69 (51%) | 62 (49%) | 0.7 |
| Hemoglobin, g/dl median (range) | 18 (14.8–24) | 18 (15.8–23) | 18 (14.8–24) | 0.9 |
| Leukocytes, × 109/l; median (range) | 11.7 (4.3–59.3) | 11.7 (4.7–59.3) | 11.5 (4.3–35.5) | 0.6 |
| Leukocytes⩾11x109/l; median (range) | 142 (57%) | 73 (56%) | 69 (59%) | 0.6 |
| Leukocytes⩾15x109/l; median (range) | 58 (23%) | 33 (25%) | 25 (21%) | 0.5 |
| Platelets, × 109/l; median (range) | 454 (44–2747) | 456 (78–1720) | 450 (44–2747) | 0.4 |
| Platelets⩾1.000 x109/l; median (range) | 14 (6%) | 9 (7%) | 5 (4%) | 0.3 |
| Presence of palpable splenomegalyn (%) N evaluable=233 | 60 (26%) | 28 (23%) | 32 (29%) | 0.3 |
| Presence of pruritus n (%) N evaluable=253 | 83 (33%) | 40 (31%) | 43 (35%) | 0.5 |
| Presence of erythromelagia n (%) N evaluable=226 | 14 (6%) | 6 (6%) | 8 (7%) | 0.7 |
| WHO PV risk stratification | 0.07 | |||
| Low risk | 81 (31%) | 35 (26%) | 46 (36%) | |
| High risk | 181 (69%) | 100 (74%) | 81 (64%) | |
| Thrombosis history at diagnosis | 74 (28%) | 40 (30%) | 34 (27%) | 0.6 |
| Thrombotic events after diagnosis | 59 (23%) | 31 (23%) | 28 (22%) | 0.9 |
| Cytogenetics categories N evaluable=142 | ||||
| Normal cytogenetic | 115 (81%) | 64 (83%) | 51 (78%) | 0.5 |
| Favorable cytogenetica | 136 (96%) | 73 (95%) | 63 (97%) | 0.5 |
| JAK2 n (%) N evaluable=258 | 250 (97%) | 128 (96%) | 122 (98%) | 0.2 |
| TET2 n (%) N evaluable=80 | 16 (20%) | 11 (23%) | 5 (15%) | 0.4 |
| ASXL1 n (%) N evaluable=80 | 8 (10%) | 6 (13%) | 2 (6%) | 0.3 |
Abbreviations: BM, bone marrow; PV, polycythemia vera; WHO, World Health Organization.
a
Favorable karyotype: normal karyotype or sole or two abnormalities that do not include the below-listed unfavorable cytogenetic abnormalities. Unfavorable karyotype: complex karyotype or sole or two abnormalities that include +8, 7/7q-, i(17q), 5/5q-, 12p-, inv(3) or 11q23 rearrangement.